These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 28125365)

  • 1. Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States.
    Wang J; Chmielowski B; Pellissier J; Xu R; Stevinson K; Liu FX
    J Manag Care Spec Pharm; 2017 Feb; 23(2):184-194. PubMed ID: 28125365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
    Oh A; Tran DM; McDowell LC; Keyvani D; Barcelon JA; Merino O; Wilson L
    J Manag Care Spec Pharm; 2017 Jun; 23(6):653-664. PubMed ID: 28530525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal.
    Miguel LS; Lopes FV; Pinheiro B; Wang J; Xu R; Pellissier J; Laires PA
    Value Health; 2017 Sep; 20(8):1065-1073. PubMed ID: 28964438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma.
    Paul E; Konidaris G; Cope S; Chen CI; Keeping S; Xu Y; Atsou K; Ayers D; Guyot P; Sasane M; Mojebi A; Kuznik A
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1513-1525. PubMed ID: 34351214
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.
    Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Liu FX; Wang J; Aguiar-Ibáñez R
    J Med Econ; 2019 Oct; 22(10):981-993. PubMed ID: 31012765
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
    Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
    J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
    [No Abstract]   [Full Text] [Related]  

  • 8. An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.
    Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Scherrer E; Wang J; Aguiar-Ibáñez R
    Clin Drug Investig; 2020 Jul; 40(7):629-643. PubMed ID: 32418051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
    Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong.
    Loong HH; Wong CKH; Leung LKS; Tan SC; Jen J; Lee MYK; Aguiar-Ibáñez R; Wang J
    Cost Eff Resour Alloc; 2020; 18():2. PubMed ID: 31969794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States.
    Huang M; Lou Y; Pellissier J; Burke T; Liu FX; Xu R; Velcheti V
    J Med Econ; 2017 Feb; 20(2):140-150. PubMed ID: 27571538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Pembrolizumab Versus Carboplatin and Paclitaxel in Patients With Unresectable or Metastatic Melanoma After First-Line Treatment in China.
    Tang WX; Shao RJ; Wang J; Scherrer E; Ma AX; Aguiar-Ibáñez R
    Value Health Reg Issues; 2022; 27():99-107. PubMed ID: 34922053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
    Watson TR; Gao X; Reynolds KL; Kong CY
    JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.
    Huang M; Lou Y; Pellissier J; Burke T; Liu FX; Xu R; Velcheti V
    Pharmacoeconomics; 2017 Aug; 35(8):831-844. PubMed ID: 28620848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.
    Chan A; Dang C; Wisniewski J; Weng X; Hynson E; Zhong L; Wilson L
    Am J Clin Oncol; 2022 Feb; 45(2):66-73. PubMed ID: 34991104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.
    Barzey V; Atkins MB; Garrison LP; Asukai Y; Kotapati S; Penrod JR
    J Med Econ; 2013; 16(2):202-12. PubMed ID: 23057750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
    Wu B; Shi L
    JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.
    Almutairi AR; Alkhatib NS; Oh M; Curiel-Lewandrowski C; Babiker HM; Cranmer LD; McBride A; Abraham I
    JAMA Dermatol; 2019 Jan; 155(1):22-28. PubMed ID: 30477000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
    Kohn CG; Zeichner SB; Chen Q; Montero AJ; Goldstein DA; Flowers CR
    J Clin Oncol; 2017 Apr; 35(11):1194-1202. PubMed ID: 28221865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.